Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33857412

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 May
First author
Eggermont AMM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 May;22(5):573-575. doi: 10.1016/S1470-2045(21)00125-X.
    note
    Source null
    related pmid
    33857410
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Jul;22(7):e299. doi: 10.1016/S1470-2045(21)00346-6.
    note
    Source null
    related pmid
    34197759
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Jul;22(7):e300. doi: 10.1016/S1470-2045(21)00354-5.
    note
    Source null
    related pmid
    34197760
    relationship
    Comment in

Authors and identifiers

  1. name
    Eggermont AMM
    type
    Author
  2. name
    Blank CU
    type
    Author
  3. name
    Mandalà M
    type
    Author
  4. name
    Long GV
    type
    Author
  5. name
    Atkinson VG
    type
    Author
  6. name
    Dalle S
    type
    Author
  7. name
    Haydon AM
    type
    Author
  8. name
    Meshcheryakov A
    type
    Author
  9. name
    Khattak A
    type
    Author
  10. name
    Carlino MS
    type
    Author
  11. name
    Sandhu S
    type
    Author
  12. name
    Larkin J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Eggermont AMM
    type
    Author
  2. name
    Blank CU
    type
    Author
  3. name
    Mandalà M
    type
    Author
  4. name
    Long GV
    type
    Author
  5. name
    Atkinson VG
    type
    Author
  6. name
    Dalle S
    type
    Author
  7. name
    Haydon AM
    type
    Author
  8. name
    Meshcheryakov A
    type
    Author
  9. name
    Khattak A
    type
    Author
  10. name
    Carlino MS
    type
    Author
  11. name
    Sandhu S
    type
    Author
  12. name
    Larkin J
    type
    Author
bibliography ids
  1. nci-bib-00a94f3c1899674e19c891f7
book metadata
content sha256
2df132a4bff1d59b1a7cbd13f99242936136136533229d6ea9e3249907215a79
document type
citation
dois
  1. 10.1016/S1470-2045(21)00065-6
electronic publication date
display
2021 Apr 12
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33857412
immutable id
pubmed:33857412@2df132a4bff1d59b1a7cbd13f99242936136136533229d6ea9e3249907215a79
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
643-654
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 May;22(5):573-575. doi: 10.1016/S1470-2045(21)00125-X.
    note
    Source null
    related pmid
    33857410
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Jul;22(7):e299. doi: 10.1016/S1470-2045(21)00346-6.
    note
    Source null
    related pmid
    34197759
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Jul;22(7):e300. doi: 10.1016/S1470-2045(21)00354-5.
    note
    Source null
    related pmid
    34197760
    relationship
    Comment in
outcomes validated
false
pmid
33857412
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
bdeb8c8fa9ef6e53f5b9c7599548569bbb1dd7096c62b01e510feac7980be682
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 May
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33857412/
title
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Preserved source evidence · Not medical advice